- Home
- SUPN vs EVT Comparison
SUPN vs EVT Comparison
Compare SUPN & EVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- EVT
- Stock Information
- Founded
- SUPN 2005
- EVT 2003
- Country
- SUPN United States
- EVT United States
- Employees
- SUPN N/A
- EVT N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- EVT Finance Companies
- Sector
- SUPN Health Care
- EVT Finance
- Exchange
- SUPN Nasdaq
- EVT Nasdaq
- Market Cap
- SUPN 1.8B
- EVT 1.7B
- IPO Year
- SUPN 2012
- EVT N/A
- Fundamental
- Price
- SUPN $32.50
- EVT $23.97
- Analyst Decision
- SUPN Hold
- EVT
- Analyst Count
- SUPN 2
- EVT 0
- Target Price
- SUPN $36.00
- EVT N/A
- AVG Volume (30 Days)
- SUPN 756.0K
- EVT 115.5K
- Earning Date
- SUPN 08-05-2025
- EVT 01-01-0001
- Dividend Yield
- SUPN N/A
- EVT 8.32%
- EPS Growth
- SUPN N/A
- EVT N/A
- EPS
- SUPN 1.11
- EVT 6.63
- Revenue
- SUPN $667,997,000.00
- EVT $69,404,302.00
- Revenue This Year
- SUPN N/A
- EVT N/A
- Revenue Next Year
- SUPN $12.02
- EVT N/A
- P/E Ratio
- SUPN $30.34
- EVT $3.55
- Revenue Growth
- SUPN 11.82
- EVT N/A
- 52 Week Low
- SUPN $27.05
- EVT $19.20
- 52 Week High
- SUPN $40.28
- EVT $25.83
- Technical
- Relative Strength Index (RSI)
- SUPN 57.05
- EVT 53.91
- Support Level
- SUPN $32.91
- EVT $23.80
- Resistance Level
- SUPN $34.40
- EVT $24.41
- Average True Range (ATR)
- SUPN 0.94
- EVT 0.23
- MACD
- SUPN 0.16
- EVT -0.06
- Stochastic Oscillator
- SUPN 64.66
- EVT 31.06
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.